Department of Oral and Maxillofacial Surgery, University of California, San Francisco, California, USA.
Department of Oral and Maxillofacial Pathology, Medicine and Surgery, Temple University, Philadelphia, Pennsylvania, USA.
Int J Oral Maxillofac Surg. 2021 Aug;50(8):1019-1022. doi: 10.1016/j.ijom.2020.12.013. Epub 2021 Jan 16.
Denosumab has been suggested as a medical treatment for central giant cell granuloma of the jaws. This study included eight patients, seven female and one male, aged between 19 and 32 years, with biopsy-proven central giant cell granuloma of the mandible. The patients were treated with subcutaneous injections of 120 mg of denosumab in a regime consisting of three injections at weekly intervals followed by five injections at monthly intervals over a 6-month period. They were followed up for between 60 and 71 months clinically and radiographically with panoramic radiographs and cone beam computed tomography scans. All of the lesions became calcified radiographically and asymptomatic clinically. They did not reduce in size, but to date only one patient has requested surgical remodeling. There has been no recurrence or regrowth in over 5 years.
地舒单抗被提议用于治疗颌骨中央性 giant cell 肉芽肿。本研究纳入了 8 名患者，7 名女性，1 名男性，年龄 19 至 32 岁，均经下颌骨中央性 giant cell 肉芽肿活检证实。患者接受了皮下注射 120mg 地舒单抗治疗，方案为每周注射 3 次，共 6 个月，随后每月注射 5 次。他们接受了 60 至 71 个月的临床和影像学随访，包括全景片和锥形束 CT 扫描。所有病变在影像学上均钙化且临床无症状。它们的大小没有缩小，但迄今为止只有 1 名患者要求手术整形。5 年多来，没有复发或再生长。
